allergic rhinitis (AR) market

DelveInsight has launched a new report on “Allergic Rhinitis (AR)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’sAllergic Rhinitis (AR)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Allergic Rhinitis (AR), historical and forecasted epidemiology as well as the Allergic Rhinitis (AR) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

As per the study conducted by Akhouri et al. 2021: 

  • The prevalence of Allergic Rhinitis in the United States based on physician diagnosis is approximately 15%; however, the prevalence is estimated to be as high as 30% based on patients with nasal symptoms.

As per the study conducted by Jean Bousquet et al. 2020: 

  • Allergic Rhinitis often begins early in life, with a prevalence of more than 5% at 3 years of age. 
  • The prevalence of AR increased from the 1990s to the early years of the first decade of the twenty-first century in many low and middle-income countries (LMICs) but decreased or had little change in western Europe.

Key benefits of the report:

  1. The Allergic Rhinitis (AR) Market report covers a descriptive overview and comprehensive insight of the Allergic Rhinitis (AR) epidemiology and Allergic Rhinitis (AR) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Allergic Rhinitis (AR) market report provides insights into the current and emerging therapies.
  3. Allergic Rhinitis (AR) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Allergic Rhinitis (AR) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Allergic Rhinitis (AR) market.

Request for sample pages:

Allergic Rhinitis (AR) Overview

Allergic Rhinitis (AR), also known as hay fever, is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea, and sneezing. 

The key players involved in the Allergic Rhinitis (AR) market:

  1. EMS
  2. Regeneron Pharmaceuticals
  3. ALK-Abelló A/S 
  4. Bayer
  5. Inmunotek S.L. 
  6. Allergy Therapeutics

The launch of the emerging therapies is expected to significantly impact the Allergic Rhinitis (AR) treatment scenario in the upcoming years:-

Drug covered

  1. Magnólia Nasal Gel
  2. Anti-Bet v 1 
  3. HDM SLIT-tablet 
  4. Azelastine hydrochloride (BAYR9258)
  5. MM09-SIT-023
  6. PQ Grass 27600 SU

Request a free sample report @

Table of Contents

  1. Report Introduction
  2. Executive Summary
  3. SWOT analysis
  4. Allergic Rhinitis (AR) Patient Share (%) Overview at a Glance
  5. Allergic Rhinitis (AR) Market Overview at a Glance
  6. Allergic Rhinitis (AR) Disease Background and Overview
  7. Allergic Rhinitis (AR) Epidemiology and Patient Population
  8. Country-Specific Patient Population of Allergic Rhinitis (AR) 
  9. Allergic Rhinitis (AR) Current Treatment and Medical Practices
  10. Unmet Needs
  11. Allergic Rhinitis (AR) Emerging Therapies
  12. Allergic Rhinitis (AR) Market Outlook
  13. Country-Wise Allergic Rhinitis (AR) Market Analysis (2017–2030)
  14. Market Access and Reimbursement of Therapies
  15. Market drivers
  16. Market barriers
  17. Appendix
  18. Allergic Rhinitis (AR) Report Methodology
  19. DelveInsight Capabilities
  20. Disclaimer
  21. About DelveInsight

Related Reports:

Allergic Rhinitis (AR)-Pipeline Insights, 2021

Allergic Rhinitis-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Allergic Rhinitis market. A detailed picture of the Allergic Rhinitis pipeline landscape is provided, which includes the disease overview and Allergic Rhinitis treatment guidelines.

Allergic Rhinitis-Epidemiology Forecast to 2030

DelveInsight’s ‘Allergic Rhinitis-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis {;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kritika Rehani

Email: [email protected]

City: Albany

State: New York

Country: United States